Center Stage / the conversation

Liz Parrish

Founder & CEO, BioViva Sciences

Their story

Read the full guest story

Elizabeth (Liz) Parrish, MBA, is the Founder and CEO of BioViva Sciences USA Inc., a biotechnology company based on Bainbridge Island, Washington, that is developing and licensing gene therapies to slow and reverse biological aging. She is widely recognized as "Patient Zero" — the first human being in history to undergo gene therapy specifically designed to combat the hallmarks of aging, a distinction she earned in September 2015 when she flew to Bogotá, Colombia, and received two experimental therapies: one targeting telomere lengthening via telomerase activation (hTERT), and a second inhibiting myostatin to counteract age-related muscle loss. That decision, made secretly and without informing her own family, became one of the most discussed acts of self-experimentation in modern biotech history. Parrish's path into longevity science was not academic — it was personal. In 2013, her son was diagnosed with Type 1 diabetes, and the encounter with standard medical care left her unsatisfied. She began attending scientific conferences, including the SENS Foundation's sixth biennial conference in Cambridge, England, where she engaged directly with researchers like Harvard geneticist George Church. She recognized that the science of gene therapy was far ahead of its clinical deployment, that therapies proven in animals had not been given a path to human trials at any reasonable pace, and that the regulatory and financial architecture of medicine was actively delaying treatments that could save lives. She decided to build the company that would push these therapies forward. BioViva Sciences was founded in 2014, and within a year Parrish had made herself its first patient. The results she has reported from her own case are striking. Prior to the 2015 treatment, her biological age (measured via T-lymphocyte telomere length) registered at the equivalent of a 66-year-old — 22 years older than her chronological age. Six months after treatment, telomere length had increased by approximately 20 years, from 6.71kb to 7.33kb, as measured by SpectraCell Laboratories and independently reviewed by HEALES and the Biogerontology Research Foundation. She repeated the gene therapy in 2020, after which her biological markers declined again. As of her 55th birthday, she reports her epigenetic age is approximately 33 and her telomere-based biological age registers in the 20s. Beyond her own case, Parrish has built BioViva into a global licensing and research platform. The company has developed a proprietary CMV-based gene therapy delivery platform alongside AAV vectors, and is developing therapies targeting telomere extension, follistatin (muscle preservation and performance), and klotho (cognitive enhancement). BioViva has worked with Rutgers University and holds patents in AAV-based gene therapies. Parrish has also structured access through offshore licensing partners, making therapies available in countries including Mexico, Colombia, the Bahamas, and Honduras at a fraction of US costs, while simultaneously building nonprofit pipelines to treat patients — including those with childhood diseases — at no charge. She has disclosed a pipeline in Switzerland focused on putting Type 1 diabetes into remission using patients' own genetically modified cells. Parrish is a founding member of the International Longevity Alliance and an affiliated member of the Complex Biological Systems Alliance (CBSA), a Mensa-based scientific platform. She was formerly Secretary of the Board of the Regenerative Technology Alliance and Chief Marketing Officer at RNAx Ltd., an RNA therapy company. She has spoken at the WIRED Health conference in London, delivered a TEDx talk titled "Gene Therapy to Engineer Healthy Longevity," and has been profiled by the BBC World Service, Outside Magazine, Forbes, MIT Technology Review, Vice, and Wired. She is a vocal critic of the pharmaceutical subscription model, arguing that long-duration gene therapies — which can maintain protein expression for 10 to 15 years — represent an existential challenge to chronic disease drug economics, and that the United States' position as the world's most heavily medicated country while maintaining the shortest lifespan among industrialized nations is not a paradox but a consequence of a broken incentive structure.

Center Stage Gene therapy for biological aging and longevity Telomere biology, telomerase activation (hTERT), and cellular senescence Follistatin gene therapy and muscle preservation Klotho and cognitive enhancement via gene therapy PGC1-alpha, mitochondrial function, and metabolic optimization Self-experimentation ethics and N-of-1 research methodology Offshore clinical access and international gene therapy licensing Pharmaceutical disruption and the economics of chronic disease Biomarker measurement: epigenetic clocks, telomere testing, and CRP Type 1 diabetes and childhood disease gene therapy pipelines Biotech entrepreneurship and private-company regulatory strategy The International Longevity Alliance and global longevity advocacy

In their own words

Patient Zero: the first human gene therapy for aging

It's a first experiment in the world with these gene therapies in this combination. And eight months later, my husband read it in Wired magazine and that's when we decided to have the conversation.

Parrish describing the secrecy around her September 2015 self-experiment in Bogotá — she said nothing to her husband or children for eight months, underscoring the high personal stakes and the genuine medical unknown she was operating in as the first human to attempt this particular combination of therapies.

Telomere biology and the mechanics of aging

Short telomeres are associated with all the diseases of aging and when your cells can no longer divide it's because these caps get too short — and then you're pretty much done.

Parrish giving the hosts a plain-language explanation of why telomere length is the foundational biological mechanism her work targets — connecting cellular senescence, the loss of division capacity, and the cascade of end-stage diseases that follow from it.

Results: telomere lengthening and biological age reversal

About two months after the gene therapy, my telomeres were lengthened by 20 years and they continue to lengthen. I redid the gene therapy in 2020 and they lengthened significantly again.

Parrish describing the measurable, documented outcome of her 2015 treatment — telomere elongation from a biological age of 66 to one matching her chronological age, independently verified and subsequently improved further after her 2020 repeat treatment.

The failed paradigm of prescription medicine

The United States is the most prescribed country in the world and we have the shortest lifespan of all the industrialized countries. We're 5% of the population. We use 80% of the pills.

Parrish framing the structural problem with modern Western medicine — that maximum pharmacological intervention has not produced maximum longevity, and that this data point is central to her argument for why the paradigm needs to be replaced, not improved.

Gene therapy vs. the pharmaceutical subscription model

The gene therapies will last in your body for 10 to 15 years before the protein expression goes down. So this is more of a set it and forget it and get back to your lifestyle.

Parrish articulating one of the most disruptive commercial implications of gene therapy for aging — that a single administration can produce lasting benefit over a decade-plus timeframe, in direct contrast to the chronic, recurring prescription model that underpins pharmaceutical revenue.

Ethics of gene therapy and reframing 'playing God'

I mean, a lot of people look at this technology and say, is this playing God? But they don't really take into their mind what open heart surgery is. If we can start to just by an IV injection infuse you with genes that keep you from having to have your chest opened up — this is really beautiful medicine.

Parrish reframing the ethics of gene therapy against procedures that are already accepted as standard care. Her argument: the invasiveness comparison runs the other direction — an IV injection is gentler than open-heart surgery, and calling one 'natural' while calling the other 'playing God' is an inconsistency worth confronting.

Accessibility and the cost barrier in gene therapy

We are the only company in the world not only to offer these therapies, but to get nonprofits behind us and get people treated for free. So we do try to meet the unmet need of people who could not otherwise afford these therapies.

Parrish responding directly to the criticism that longevity medicine is the province of the ultra-wealthy — acknowledging the cost reality while distinguishing BioViva's nonprofit-backed access programs from purely commercial competitors.

The moral case for scientific boldness and the cost of skepticism

Skeptics shut people down because what they tell you is — I don't have to read, I don't have to learn about it. We are slowing and reversing aging in animals all the time. We need to do it in humans. Science was made for humans. It was made for people, especially people who are sick.

Parrish's closing argument on the moral cost of scientific skepticism — distinguishing between rigorous scientific critique (which she supports) and reflexive dismissal, and arguing that the people harmed by the latter aren't abstract: they are sick children and aging adults who could have benefited from therapies already proven in model organisms.

Appearances & videos

Liz Parrish: She Injected Herself With Gene Therapy to Reverse Aging

Original interview details

She Injected Herself With Gene Therapy to Reverse Aging

Episode #CS-002

Center Stage

Mornings in the Lab · Center StageFebruary 11, 2026Watch →

From the interview

Short telomeres are associated with all the diseases of aging — when your cells can no longer divide it's because these caps get too short. And then you're pretty much done.

The United States is the most prescribed country in the world and we have the shortest lifespan of all the industrialized countries. We're 5% of the population. We use 80% of the pills.

What are we going to show our children? Do we just show him that we give up and bake cookies and take insulin — or do we go do something to change the world?

Questions & answers

What exactly did Liz Parrish do in 2015 and why does it matter?

In September 2015, at age 44, Liz Parrish flew to Bogotá, Colombia and received two experimental gene therapies developed by her company BioViva: one targeting telomerase activation (hTERT) to lengthen telomeres, and a second inhibiting myostatin to counteract muscle loss. The procedures, administered through over 100 injections in a single clinic session, had never been combined in a human before. She did it because these therapies had shown compelling results in animal models but faced no near-term path to US clinical trials, and she believed the ethical cost of waiting — measured in lives — exceeded the risk of self-experimentation. The results, independently verified by HEALES and the Biogerontology Research Foundation, showed her telomeres had lengthened by the equivalent of 20 years within six months, making her case the first documented evidence of telomere reversal in a living human via gene therapy.

What are telomeres and why does lengthening them matter for aging?

Telomeres are the protective caps at the ends of every chromosome — often compared to the plastic tips on shoelaces. With every cell division, they shorten slightly. When they become critically short, cells enter a state called senescence (they can no longer divide safely), which drives the accumulation of dysfunction across tissues and organs that we experience as aging and ultimately as end-stage diseases like cancer, heart disease, and dementia. Parrish explains it plainly: 'Short telomeres are associated with all the diseases of aging and when your cells can no longer divide it's because these caps get too short.' The gene therapy she received activates telomerase, the enzyme that adds length back to telomeres, temporarily reversing this clock. BioViva has measured her T-lymphocyte telomere length at multiple points over nine years, using three independent labs, and consistently observed lengthening following each treatment.

How much does BioViva's gene therapy cost and who can access it?

US-approved gene therapies for aging-related conditions run from two to seven million dollars. BioViva operates through offshore licensing partners — in Mexico, Colombia, the Bahamas, Honduras, and Switzerland — where regulatory frameworks allow access at a fraction of those costs, though Parrish acknowledges therapies remain 'cost prohibitive' for most individuals. The company has also structured 'buyer clubs,' in which groups of patients pool costs to access a single licensed therapy round at a substantially lower per-person price. Parrish is emphatic that cost reduction is central to her mission: 'I am here to create affordable therapies for the world.' BioViva also supports nonprofit partnerships that fund treatment for patients — including those with childhood diseases — at no charge.

What is Liz Parrish's biological age today and how is it measured?

As of age 55 (chronological), Parrish reports her biological age as approximately 33 by epigenetic markers, and in the 20s by telomere length as measured in T-lymphocytes. BioViva uses three independent labs for testing. She is careful to note that different markers produce different readings, and she is openly critical of current biological age measurement as a complete framework: 'The future human is going to register very differently than how we mark aging today.' She views low CRP (C-reactive protein), stable metabolic markers, and upregulated regenerative signaling as the more meaningful indicators of her therapy's effectiveness, alongside the disappearance of the aches, limitations, and recovery difficulties that characterized her condition before treatment.

Why isn't BioViva conducting FDA-approved clinical trials in the United States?

Parrish has addressed this question repeatedly and her answer is both strategic and principled. Operating as a private company outside US jurisdiction gives BioViva the mobility to conduct first-in-human studies and license therapies offshore while US regulatory timelines for novel gene therapy remain measured in decades. She points out that BioViva was able to treat herself, conduct the first gene therapy study in human dementia, and mobilize licensing deals precisely because it was not constrained by public-company governance or US FDA pre-approval requirements. She is also developing what she calls a 'Best Choice Medicine' regulatory model that would create a more efficient approval pathway for genetic therapies. Parrish does not oppose regulatory oversight — she supports it — but argues that the current pace of FDA approval for gene therapy imposes a death toll that regulators do not account for: 'If we have the treatment for aging right now, it would be an act against humanity if you don't put these treatments forward.'

What is the connection between Liz Parrish's work and her son's Type 1 diabetes?

Parrish's entry into longevity science was triggered by her son's 2013 Type 1 diabetes diagnosis. Encountering a medical system that could manage the disease but not cure it, she channeled her urgency into genetics research — attending conferences, engaging with scientists, and ultimately founding BioViva. Every gene therapy BioViva targets, she says, is also designed to address a childhood disease. On the show she revealed a specific pipeline: BioViva is currently working with a research center in Switzerland to put Type 1 diabetes into remission using patients' own stem cells, genetically modified and returned to the body. 'I found it took longer, but we are creating the first pipeline to a patient's own cells, putting type 1 diabetes in remission — it took all of these years to find the right doctors, the right research centers that believed in me.'

The full conversation

Read the transcript

If you're over 40, you felt it. Your body doesn't bounce back and the clock starts talking louder. Most guys don't fear aging. They fear losing capability, strength, clarity, and the role they're supposed to hold. Today's guest lives in that exact pressure. She isn't a wellness influencer. She's someone pushing the edge of medicine. Liz is the CEO and founder of a revolutionary biotech company based near Seattle on Bainbridge Island. She's known as patient zero, the first person to undergo gene therapy with the goal of reversing biological aging. In September 2015, at age 44, she flew to Bogota. She received experimental therapies targeting telomeres and muscle preservation. Liz says blood tests showed her telomeres looked about 20 years younger. She since pursued klotho, follistatin, and PGC1 alpha. She also says over 300 people worldwide have accessed gene therapies through her company's network. When people call it playing God, she calls it medicine catching up to suffering. That argument matters, especially when your health is on the line. Keith: Johnny, what if I told you there's a woman out there, a mom from Seattle? She secretly flew to Colombia, didn't tell her husband or her kids, and had over a hundred needles shoved into her body in a clinic? Not for cosmetic reasons, not because she was sick, but because she decided that aging itself is a disease and she was going to be the guinea pig to prove it. Elizabeth Parrish, into the lab with Keith and John. Liz: How's it going? Good morning from Seattle. Keith: So, hold on. You get on the airplane. You don't tell the husband and kids you're going to Colombia to get some needles stabbed in your body. I don't care about anything else other than how did that conversation go when you got home? Liz: Well, it went really well for me for about eight months because I decided not to bring it up because I needed to recover and to let the gene therapies work. And I kept meaning to tell the family, but I really needed things to go normally because it was a first experiment in the world with these gene therapies in this combination. And eight months later, my husband read it in Wired magazine and that's when we decided to have the conversation. Keith: Are you still married? Liz: Yeah, I am. He's a pretty patient guy.

Open transcript page →

Guest gallery

Announcement card · Pre-show shareable graphic generated by the Authority Page Builder.

Conversation topics

Center Stage introduction: the woman who secretly flew to Colombia · ~3 minutes · The hosts frame Liz Parrish's story before she appears: a Seattle mom who didn't tell her husband or children, flew to Colombia, and had over 100 needles injected into her body — not because she was sick, but because she had decided aging itself was a disease. The introduction sets up the show's hook and the tension between her ordinary personal life and the extraordinary nature of what she did. · The secret that lasted eight months: husband, Wired magazine, and the conversation · ~4 minutes · Parrish explains why she kept her 2015 Bogotá trip from her family for eight months — she needed to monitor the experiment without interference and let the therapy work. The reveal came when her husband read about it in Wired. She describes his reaction as initially upset, and her response as the argument that stopped the conversation: pointing to their son with Type 1 diabetes and asking what they were going to show him — that they gave up, or that they went to change the world. · Telomeres explained: the shoelace metaphor and the biology of cellular aging · ~5 minutes · Parrish and the hosts walk through telomere biology from first principles — the DNA shoelace metaphor, the shortening process with each cell division, genomic instability, cellular senescence, and the link to every major age-related disease. Discussion includes the peptide epithalon and its role as a milder telomere support, with Parrish clarifying what her hTERT gene therapy accomplished that epithalon could not: actual measurable lengthening in T-lymphocytes. · The data: before and after measurements, three labs, and 20 years of biological reversal · ~4 minutes · Parrish presents the specific results from her treatment: telomere length increased by the equivalent of 20 years within months, as independently verified by HEALES and the Biogerontology Research Foundation. She explains how BioViva measures biological age — long-term and short-term markers, metabolic markers, and epigenetic clocks — and defends the primacy of data in longevity medicine while acknowledging that how a patient feels is also a meaningful data point, not noise. · Data vs. feelings: how BioViva separates signal from noise in experimental medicine · ~4 minutes · Parrish engages directly with the hosts' discussion of how they each personally use biometric data — the tension between relying on how you feel versus quantified markers. She draws a distinction between fast-moving metabolic markers (which fluctuate hourly and can mislead) and slow-moving, long-term markers of beneficial health, which she argues are the real diagnostic signal for gene therapy outcomes. · Cost, access, and the offshore model: buyer clubs, nonprofits, and the price of hope · ~5 minutes · Parrish addresses the cost reality of gene therapy directly: US-approved therapies run $2–7 million. Through offshore licensing partners, BioViva has brought that cost down to a fraction, though it remains prohibitive for most individuals. She describes the buyer-club model, her nonprofit partnerships for free treatment, and her explicit goal of making these therapies available to the world — including people who 'desperately need these therapies' and cannot pay. · Playing God vs. beautiful medicine: the ethics of gene therapy for aging · ~3 minutes · Parrish reframes the 'playing God' critique by comparing gene therapy to procedures already accepted as standard of care. She argues that the ethical logic runs the other direction: if you can prevent open-heart surgery, pig valve transplants, and dementia through an IV injection, it is 'really beautiful medicine.' She also connects this to Big Pharma's resistance — gene therapies that last 10–15 years per dose are structurally incompatible with the chronic-prescription revenue model. · Peter Attia, Bryan Johnson, and the longevity influencer landscape · ~4 minutes · Parrish is asked about other prominent longevity voices — Peter Attia and the billionaire biohacker spending $1B to reverse his aging. Her response is measured and pointed: lifestyle optimization is important and is the foundation, but it comes with diminishing returns as we age. The future belongs to gene therapy and bioelectric signals (citing the work of Michael Levin). Diet and exercise will not produce an outlived person. 'Do not buy that.' · The son, the diagnosis, and the promise in the hospital room · ~4 minutes · The emotional anchor of the episode. Parrish is asked directly: when she looks at her son — a young man still living with Type 1 diabetes, the same disease that sent her down this path — does she feel closer to keeping the promise she made, or further away? She shares that she is now building a pipeline in Switzerland specifically to put Type 1 diabetes into remission using patients' own cells. 'My vision has never stopped. It actually took this long to meet the right people and build the right pipelines.' · The Shark Tank loneliness clip and closing thoughts on belief, critics, and the future · ~3 minutes · Keith shares a Robert Herjavec clip about the loneliness of entrepreneurship — the late nights, the disbelief, the need to carry conviction alone. Parrish resonates with it immediately, noting that sometimes you don't tell your family because you don't want to freak them out. She closes with a call to scientific literacy: skeptics don't live as long because they shut people down from learning. The invitation is to read papers, engage with the science, and recognize that what is being proven in animals right now will define human health in the coming decades.